Objective To study the effect of tanshinone ⅡA on the expression of P-selectin and ICAM-1 after cerebral ischemia reperfusion (I/R)injury in rats. Methods Rats were randomly divided into 4 groups: Sham operated group, I/R group, low dose Tan ⅡA treated group and high dose Tan ⅡA treated group. The focal middle cerebral artery occlusion (MCAO) model was made by suture-occluded method. Rats were pretreated with Tan ⅡA, ig for 3d,respectively before MCAO. After 90min MCAO following 24 hours of reperfusion, the expression of P-selectin and ICAM-1 was detected with using immunohistochemistry method. Result Compared with sham operated group, the expression of P-selectin and ICAM-1 increased after reperfusion for 24 hours in the ischemic territory(all P＜0.01).Compared with I/R group, the expression of P-selectin and ICAM-1 decreased in a dose dependent manner in low and high dose Tan ⅡA treated group(P＜0.01).Compared with that of I/R group, cerebral infarction volume was decreased in a dose dependent manner in low dose Tan ⅡA treated group and high dose Tan ⅡA treated group(all P＜0.01).The change of ischemic impairment in low or high dose Tan ⅡA treated group was less than that in IR group, and the change of ischemic impairment in high dose Tan ⅡA treated group was less than that in low dose Tan ⅡA treated group. Conclusion Tan ⅡA may reduce cerebral ischemia-reperfusion inflammation injure by decreasing the expression of p-selectin and ICAM-1.Tan ⅡA plays protective effect on cerebral ischemia injury, especially when high dose of Tan ⅡA(30mg/kg)was used.

Objective It is to observe the influence of atorvastat on the clinical therapeutic effect in the patients with cerebral infarction and lipid lowering, C-reactive protein level. Methods 60 patients with cerebral infarction are admined by atorvastatin 20mg,orally taking, 1 time per day,course of treatment for 4 weeks. Observing the variation of the high sensitivity C-reactive protein(hs-CRP) and concentration of blood fat in the circa about treatment. Results Treatment group's excellence rate is 70.0 %, total effective rate is 86.7 % after 4 weeks' atorvastatin treatment. It obviously outweighs the control group(43.3 % and 66.7 % ) ( P＜0.05 ) without evident adverse effect; TC, LDL-C significantly step clown and HDL-C(P＜0.05 ) significantly steps up comparing pretherapy. They also obviously outweigh the control group(P＜0.05 and P＜0.01 ). The blood serum hs-CRP level obviously decreases( P＜0.01 ). Conclusion Atorvastat can not only lower the lipid, but also degrade the concentration of CRP.It has significant clinical therapeutic effect while without evident adverse effect. The early use of atorvastatin can prevent and control ischemic cerebrovascular disease preferably. It can also reduce the genesis of cerebrovascular disease and improve the prognosis of cerebrovascular disease.